Skip to main content

Table 3 The steady-state plasma concentration of tamoxifen and its metabolites

From: Limited predictive value of achieving beneficial plasma (Z)-endoxifen threshold level by CYP2D6 genotyping in tamoxifen-treated Polish women with breast cancer

[ng/ml] Mean SD Median Min Max Not detecteda
N = 279 (%)
Tamoxifen 173.53 67.68 169.76 41.4 402.10 0 (0)
NDM-Tam 235.53 97.04 220.53 33.20 810.16 0 (0)
(Z)-Endoxifen + 3-OH-NDM-Tam 5.55 3.26 4.90 0.55 18.23 0 (0)
(Z)-4-OH-Tam + 3-OH-Tam 2.46 1.20 2.45 0.12 5.66 0 (0)
(E)-Endoxifen 0.02 0.07 0 0.03 0.37 249 (89.2)
4′-OH-Tam 3.13 1.32 2.93 0.37 8.72 0 (0)
4′-OH-NDM-Tam 3.84 1.93 3.56 0.19 15.66 1 (0.4)
Tam-N-oxide 13.47 7.43 11.62 1.41 58.03 0 (0)
(E)-4-OH-Tam-O-gluc 0.23 0.17 0.18 0.03 1.19 1 (0.4)
(E/Z)-4-OH-NDM-Tam-gluc 1.12 1.02 0.88 0.10 11.49 0 (0)
(E/Z)-Tam-N-gluc 0.32 0.32 0.24 0.03 2.45 1 (0.4)
(E)-α-OH-Tam 0.36 0.17 0.37 0.02 1.02 8 (2.9)
(Z)-α-OH-Tam 0.04 0.03 0.04 0.02 0.19 116 (41.6)
  1. aThe number and (%) of patients with no detectable plasma concentration of compounds